Cargando…

High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab appears promising for patients with programmed cell death ligand-1 (PD-L1)-positive solid tumors. However, data on immunotherapy for biliary tract cancers (BTC) are limited. We aimed to investigate the predictive value of PD-L1 expression as an immunotherapeutic biomarker in BTC. Patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahn, Soomin, Lee, Jong-chan, Shin, Dong Woo, Kim, Jaihwan, Hwang, Jin-Hyeok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378166/ https://www.ncbi.nlm.nih.gov/pubmed/32704067 http://dx.doi.org/10.1038/s41598-020-69366-4

Ejemplares similares

Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis
por: Jung, Kwangrok, et al.
Publicado: (2022)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
por: Park, Chan Su, et al.
Publicado: (2022)

Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
por: Kang, Junho, et al.
Publicado: (2020)

Four-Tier Pathologic Tumor Regression Grading System Predicts the Clinical Outcome in Patients Who Undergo Surgical Resection for Locally Advanced Pancreatic Cancer after Neoadjuvant Chemotherapy
por: Ahn, Soomin, et al.
Publicado: (2022)

Higher Tumor Cellularity in Resected Pancreatic Ductal Adenocarcinoma Is a Negative Prognostic Indicator
por: Cho, In Kuk, et al.
Publicado: (2020)

Completely resolved advanced biliary tract cancer after treatment by pembrolizumab: a report of two cases
por: Alshari, Osama M, et al.
Publicado: (2019)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020)

Primary Granulocyte Colony-Stimulating Factor Prophylaxis in Metastatic Pancreatic Cancer Patients Treated with FOLFIRINOX as the First-Line Treatment
por: Jung, Jae Hyup, et al.
Publicado: (2020)

Maintenance of skeletal muscle mass during FOLFIRINOX is a favorable prognostic factor in pancreatic cancer patients
por: Shin, Dong Woo, et al.
Publicado: (2021)

Association between progression-free survival and metal stent patency in patients with advanced pancreatic cancer
por: Ahn, Jinwoo, et al.
Publicado: (2022)

MicroRNA 141 Expression Is a Potential Prognostic Marker of Biliary Tract Cancers
por: Kim, Jaihwan, et al.
Publicado: (2016)

Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
por: Sun, Danyang, et al.
Publicado: (2019)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer
por: Kai, Yugo, et al.
Publicado: (2021)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma
por: Shin, Dong Woo, et al.
Publicado: (2022)

The Three P's: Parotid, PD-L1, and Pembrolizumab
por: Wiggins, Amanda, et al.
Publicado: (2019)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
por: Mirallas, O., et al.
Publicado: (2022)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience
por: Lee, Jongchan, et al.
Publicado: (2018)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer
por: Jung, Jae Hyup, et al.
Publicado: (2022)

Diagnostic Utility of the PD-L1 Immunostaining in Biopsy Specimens of Patients with Biliary Tract Neoplasms
por: Matsumoto, Kazuyuki, et al.
Publicado: (2022)

Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing()
por: Yoo, Kwai Han, et al.
Publicado: (2016)

Postoperative muscle mass restoration as a prognostic factor in patients with resected pancreatic cancer
por: Lee, Jongchan, et al.
Publicado: (2020)

Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis
por: Lee, Jong-chan, et al.
Publicado: (2018)

Clinical impact of neoadjuvant treatment in resectable pancreatic cancer: a systematic review and meta-analysis protocol
por: Lee, Jong-chan, et al.
Publicado: (2016)

The Predictive Value of PD-L1 Expression Level in Evaluating the Cost-Effectiveness of Atezolizumab/Pembrolizumab
por: Lin, Shen, et al.
Publicado: (2022)

Immunotherapy in Advanced Biliary Tract Cancers
por: Boilève, Alice, et al.
Publicado: (2021)

Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open‐Label, Phase I Trial (JVDF)
por: Arkenau, Hendrik‐Tobias, et al.
Publicado: (2018)

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2023)

Do We Really Need Additional Contrast-Enhanced Abdominal Computed Tomography for Differential Diagnosis in Triage of Middle-Aged Subjects With Suspected Biliary Pain
por: Hwang, In Kyeom, et al.
Publicado: (2015)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
por: Nishii, Yoichi, et al.
Publicado: (2022)

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma
por: Brar, Gagandeep, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9uvk7sfbsj4k3ohsd5attvut04